Menu

Blog

Archive for the ‘biotech/medical’ category: Page 1348

Oct 24, 2020

New Metastatic Breast Cancer Treatments and Breakthroughs of 2019

Posted by in categories: biotech/medical, innovation

#BreastCancerAwarenessMonth
Breast cancer treatments are always evolving and improving. In 2019, fresh perspectives to approach cancer therapy led to exciting breakthroughs for treatments in research.

Today’s treatments are more targeted and capable of altering the breast cancer disease course while also maintaining your quality of life. In recent years, many therapeutic options have emerged for treating stage 4, or metastatic breast cancer, greatly improving survival rates.


Breast cancer treatment research is ongoing and always improving the lives of those living with the condition. Here are the breakthrough treatments of 2019 as well as current treatments and information on finding a cure.

Oct 24, 2020

Tesla Model Y May Soon Get ‘Bioweapon Defense Mode’ with HEPA Filter

Posted by in categories: biotech/medical, military

Well, considering current events…


The Tesla HEPA Filter and Bioweapon Defense Mode have repeatedly proven their usefulness and even vital necessity. At the moment, only Model S and Model X have the air-cleaning feature, however, there is a high probability that the HEPA filter will be installed in Model Y.

Hacker @greentheonly/Twitter has once again noticed several updates that should be made available to Model Y. He claims that the car will receive a HEPA filter and the corresponding Bioweapon Defense Mode. He also clarified that Model 3 most likely won’t receive it at this point.

Continue reading “Tesla Model Y May Soon Get ‘Bioweapon Defense Mode’ with HEPA Filter” »

Oct 24, 2020

CRISPR turns normal body fat into a type that burns energy

Posted by in categories: bioengineering, biotech/medical

Animal studies suggest the metabolic conditions linked to obesity could be treated by using CRISPR gene editing to turn normal fat into heat-producing beige fat.

Oct 24, 2020

New imaging method reveals HIV’s sugary shield in unprecedented detail

Posted by in categories: biotech/medical, mapping

Scientists from Scripps Research and Los Alamos National Laboratory have devised a method for mapping in unprecedented detail the thickets of slippery sugar molecules that help shield HIV from the immune system.

Mapping these shields will give researchers a more complete understanding of why antibodies react to some spots on the virus but not others, and may shape the design of new vaccines that target the most vulnerable and accessible sites on HIV and other viruses.

The sugar molecules, or “glycans,” are loose and stringy, and function as shields because they are difficult for antibodies to grip and block access to the . The shields form on the outermost spike proteins of HIV and many other viruses, including SARS-CoV-2, the coronavirus that causes COVID-19, because these viruses have evolved sites on their spike proteins where glycan molecules—normally abundant in cells—will automatically attach.

Oct 24, 2020

Oxford coronavirus vaccine provides ‘strong’ immune response, analysis finds

Posted by in category: biotech/medical

‘This is only good news in our fight against the illness,’ researcher says.

Oct 23, 2020

When Start-Ups Go Into the Garage (or Sometimes the Living Room)

Posted by in categories: biotech/medical, habitats

But Silicon Valley is not the home of ingenuity for nothing. When the pandemic hit, many start-up engineers in the area, like Dr. Wessells, moved their gear into their home garages so they could keep innovating. And if it wasn’t the garage, then it was the living room.


Labs closed in the pandemic, but innovation doesn’t stop. So while some workers have the home office, engineers have the garage.

Oct 23, 2020

PESAO: An experimental setup to evaluate the perceptions of freely moving humans

Posted by in categories: biotech/medical, robotics/AI

Humans regularly tackle and solve a variety of complex visuospatial problems. In contrast, most machine learning and computer vision techniques developed so far are designed to solve individual tasks, rather than applying a set of capabilities to any task they are presented with.

Researchers at York University in Canada have been trying to better understand the mechanisms that allow humans to actively observe their environment and solve the wide range perception tasks that they encounter every day, with the hope of informing the development of more sophisticated computer vision systems. In a paper pre-published on arXiv, they presented a new experimental setup called PESAO (psychophysical experimental setup for active observers), which is specifically designed to investigate how humans actively observe the world around them and engage with it.

“The hallmark of human vision is its generality,” Prof. John K. Tsotsos, one of the researchers who carried out the study, told TechXplore. “The same brain and allow one to play tennis, drive a car, perform surgery, view photo albums, read a book, gaze into your loved one’s eyes, go online shopping, solve 1000-piece jigsaw puzzles, find lost keys, chase after his/her young daughter when she appears in danger and so much more. The reality is that as incredible as AI successes have been so far, it is humbling to acknowledge how far there still is to go.”

Oct 23, 2020

A math idea that may dramatically reduce the dataset size needed to train AI systems

Posted by in categories: biotech/medical, mathematics, robotics/AI

A pair of statisticians at the University of Waterloo has proposed a math process idea that might allow for teaching AI systems without the need for a large dataset. Ilia Sucholutsky and Matthias Schonlau have written a paper describing their idea and published it on the arXiv preprint server.

Artificial intelligence (AI) applications have been the subject of much research lately, with the development of , researchers in a wide range of fields began finding uses for it, including creating deepfake videos, board game applications and medical diagnostics.

Deep learning networks require large datasets in order to detect patterns revealing how to perform a given task, such as picking a certain face out of a crowd. In this new effort, the researchers wondered if there might be a way to reduce the size of the dataset. They noted that children only need to see a couple of pictures of an animal to recognize other examples. Being statisticians, they wondered if there might be a way to use mathematics to solve the problem.

Oct 23, 2020

PV-powered drone for emergency services

Posted by in categories: biotech/medical, drones, solar power

Netherlands-based technology companies Avy and Wattlab have conducted the first test flight of a drone prototype that is planned to be used in medical projects in Africa.


Wattlab, a Dutch clean-tech start-up founded by Sweden-based power utility Vattenfall and Delft University of Technology, and Netherlands-based drone manufacturer Avy have announced that a drone equipped with special solar foils produced by Wattlab has successfully performed its first test flight.

“The solar-powered prototype is designed to be used for urgent medical transportation, emergency services, and nature conservation,” the two companies stated, adding that the solar films were installed on the wings while maintaining aerodynamics and without increasing significantly the weight. “The solar technology developed in this project is fully integrated into the wing shape and adds no extra weight,” explained Bo Salet, founder of Wattlab.

Continue reading “PV-powered drone for emergency services” »

Oct 23, 2020

Regulatory T Cells Control the Switch From in situ to Invasive Breast Cancer

Posted by in category: biotech/medical

Ductal carcinoma in situ (DCIS) is a non-obligate precursor of breast cancer, and it only progresses to invasive breast cancer in around 40% of patients. While immune infiltrates have been observed in these early cancer lesions, their potential prognostic value is still unclear. Regulatory T (Treg) cells accumulate in advanced breast cancers, and predict poor outcome. We have shown before that ablation of Treg cells in established tumors leads to significant decrease in primary and metastatic tumor burden. In this work, we sought to investigate Treg cell function in the progression from non-invasive to invasive breast cancer lesions. To this end, we used the murine mammary tumor virus polyoma middle T (MMTV-PyMT) murine model of spontaneous, stage-wise breast carcinogenesis crossed to Foxp3DTR knock in mice, allowing Treg cell ablation by administration of diphtheria toxin. Transient targeting of Treg cells at the in situ carcinoma stage resulted in a significant increase in the number of tumor-bearing mammary glands and size of growing tumors compared with control mice. Whole mammary gland mounts and histological examination confirmed larger emergent tumor area in Treg cell-ablated mice, and revealed that these tumors were characterized by a more advanced tumor staging, with presence of early invasion, increased desmoplasia and collagen deposition. Furthermore, Treg cell ablation increased the percentage of cancer stem/progenitor cells in the mammary compartment. Interestingly, Treg cell ablation resulted in increased inflammatory cytokines IL-4 and IL-5 with a concomitant reduction in classically activated tumor associated macrophages. This TH2-biased immune regulatory mammary inflammation was consistent with the enhancement in tumor promotion that we observed. Overall, our study demonstrates that Treg cells oppose breast cancer progression at early stages, raising a cautionary note regarding the consideration of immune intervention targeted at boosting immune responses for DCIS.

While death from breast cancer has slowly declined in the past few years, mammographic screening has led to a dramatic increase in the detection of pre-invasive breast lesions in women (1–3). This paradoxical observation can be explained by the fact that only a low percentage of early breast disease progresses to invasive, metastatic carcinomas. Ductal carcinoma in situ (DCIS) is a heterogenous group of neoplastic lesions confined to the breast ducts, and can remain indolent for life in up to 60% of cases. Patients diagnosed with DCIS undergo breast-conserving therapy or mastectomy, frequently accompanied by radiotherapy and in some cases, hormonal therapy. Thus far, there are no reliable parameters to distinguish those cases that will progress, resulting in significant overtreatment.